Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

Pepa, Giuseppe Della; Russo, Marco; Vitale, Marilena; Carli, Fabrizia; Vetrani, Claudia; Riccardi, Gabriele; Vaccaro, Olga; Gastaldelli, Amalia; Rivellese, Angela Albarosa; Bozzetto, Lutgarda

doi:10.1016/j.diabres.2021.108984

Cited by 57 publications

(40 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, we performed a thorough reading and evaluation of the full texts for further eligibility assessment for the remaining fifty-five articles. Of these articles, thirty-one were excluded with reasons as follows: (1) eleven articles were conference abstracts [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ], (2) three articles were letters, editorials, and notes [ 45 , 46 , 47 ], (3) four did not involve NAFLD patients [ 48 , 49 , 50 , 51 ], (4) two studies involved HIV patients [ 52 , 53 ], (6) one study involved patients with gastroenteropancreatic neuroendocrine tumors [ 54 ], (7) two studies involved patients with polycystic ovarian syndrome [ 51 , 55 ], (8) six were interventional studies [ 56 , 57 , 58 , 59 , 60 , 61 ], and (9) two articles were published in Chinese and Portuguese [ 62 , 63 ]. The total number of articles included in the qualitative synthesis was twenty-four studies, out of which twenty-two studies were included in the quantitative synthesis [ 36 , 42 , 44 , 55 , 64 , 65 , 66 , 67 , 68 , 69 , …”

Section: Resultsmentioning

confidence: 99%

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

(1) Background: In order to avoid a liver biopsy in non-alcoholic fatty liver disease (NAFLD), several noninvasive biomarkers have been studied lately. Therefore, we aimed to evaluate the visceral adiposity index (VAI) in NAFLD and liver fibrosis, in addition to its accuracy in predicting NAFLD and NASH. (2) Methods: We searched PubMed, Embase, Scopus, and Cochrane Library, identifying observational studies assessing the VAI in NAFLD and liver fibrosis. QUADAS-2 was used to evaluate the quality of included studies. The principal summary outcomes were mean difference (MD) and area under the curve (AUC). (3) Results: A total of 24 studies were included in our review. VAI levels were significantly increased in NAFLD (biopsy-proven and ultrasound-diagnosed), simple steatosis vs. controls, and severe steatosis vs. simple steatosis. However, no significant MD was found according to sex, liver fibrosis severity, simple vs. moderate and moderate vs. severe steatosis, pediatric NAFLD, and NASH patients. The VAI predicted NAFLD (AUC 0.767) and NASH (AUC 0.732). (4) Conclusions: The VAI has a predictive value in diagnosing NAFLD and NASH, with significantly increased values in adult NAFLD patients, simple steatosis compared to controls, and severe steatosis compared to simple steatosis.

show abstract

Section: Resultsmentioning

confidence: 99%

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Among antidiabetics drugs pioglitazone, glucagon-like-peptide (GLP-1) analogues and liraglutide were found to be effective in NAFLD/NASH treatment. Pioglitazone was shown to significantly improve steatosis and inflammation, together with systemic and adipose-tissue resistance in one-year observation in patients with T2DM [51]. Research conducted by Bril et al confirmed reduction of liver fibrosis and increase in adipose tissues insulin sensitivity.…”

Section: Treatment Options Of Nafldmentioning

confidence: 95%

Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review

Głuszyńska

Lemancewicz

Dzięcioł

et al. 2021

JCM

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has considerably increased over the last years. NAFLD is currently the most common cause of chronic liver disease in the developing world. The diagnosis of NAFLD/NASH is often incidental, as the early-stage of disease is frequently free of symptoms. Most patients recognized with NAFLD have severe obesity and other obesity-related disease such as type 2 diabetes mellitus (T2DM), insulin-resistance, dyslipidemia and hypertension. The only proven method for NAFLD improvement and resolution is weight loss. Bariatric surgery leads to significant and long-term weight loss as well as improvement of coexisting diseases. There is a lot of evidence suggesting that metabolic/bariatric surgery is an effective method of NAFLD treatment that leads to reduction in steatosis, hepatic inflammation and fibrosis. However, there is still a need to perform long-term studies in order to determine the role of bariatric surgery as a treatment option for NAFLD and NASH. This review discusses current evidence about epidemiology, pathogenesis and treatment options for NAFLD including bariatric/metabolic surgery and its effect on improvement and resolution of NAFLD.

show abstract

“…PPARs are key metabolic regulators, whose agonists are therapeutic targets for NAFLD/NASH currently under evaluation in phase I to III clinical trials, including the drug Pioglitazone (Boeckmans et al , 2019; Della Pepa et al , 2021; Wu et al , 2020). The time-dependent decrease in PPAR emphasizes the importance to take proteome drift into account when evaluating PPAR agonist efficacy in hepatocyte models.…”

Section: Resultsmentioning

confidence: 99%

Dynamic human liver proteome atlas reveals functional insights into disease pathways

Mann

Niu

Geyer

et al. 2022

Preprint

View full text Add to dashboard Cite

Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteome resource at cell-type resolution to predict outcome and design therapy. Here, we quantify more than 150,000 sequence-unique peptides aggregated into 10,000 proteins across total liver, the major liver cell types, time-course of primary cell cultures and liver disease states. Bioinformatic analysis reveals that half of hepatocyte protein mass is comprised of enzymes and 23% of mitochondrial proteins, twice the proportion of other liver cell types. Using primary cell cultures, we capture dynamic proteome remodeling from tissue states to cell line states, providing useful information for biological or pharmaceutical research. Our extensive data serves as spectral library to characterize a human cohort of non-alcoholic steatohepatitis and cirrhosis. Dramatic proteome changes in liver tissue include signatures of stellate cell activation resembling liver cirrhosis and providing functional insights. We built a web-based dashboard application for the interactively exploration of our resource.

show abstract

Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

Cited by 57 publications

References 39 publications

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis

Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review

Dynamic human liver proteome atlas reveals functional insights into disease pathways

Contact Info

Product

Resources

About